https://www.mountsinai.org/care/dermatology

Mount Sinai Dermatology, 5 E 98th Street, 5th Floor, New York, NY (2026)

03/16/2026

Hidradenitis suppurativa remains one of the most challenging inflammatory skin diseases we treat, marked by painful nodules, abscesses, and draining tunnels that significantly impact quality of life. In a new study in the Journal of the European Academy of Dermatology and Venereology, Dr. Saakshi Khattri from Icahn School of Medicine at Mount Sinai and an international group of collaborators evaluated the efficacy of bimekizumab using International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the Phase three BE HEARD I and II trials. Across more than one thousand patients with moderate to severe disease, bimekizumab produced substantial reductions in disease severity, with greater improvements in IHS4 scores compared with placebo as early as Week sixteen. These findings highlight the growing role of IL seventeen pathway targeting therapies in hidradenitis suppurativa. 🔬🧬

📚 https://bit.ly/4sap9Jm

Using IHS4, a validated scoring system that dynamically incorporates draining tunnels, nodules, and abscesses, the investigators demonstrated clinically meaningful improvements sustained through forty eight weeks of treatment. The proportion of patients with severe disease fell by approximately fifty percent, and nearly one quarter of patients achieved an IHS4 score of zero, indicating complete resolution of inflammatory nodules, abscesses, and draining tunnels. Importantly, bimekizumab treatment also produced consistent reductions in lesion counts across these key disease features. 📊🧠

These findings underscore the importance of more comprehensive outcome measures such as IHS4 in clinical trials, particularly for a disease like hidradenitis suppurativa where draining tunnels contribute significantly to disease burden. As therapeutic options continue to expand, studies like this help refine how we measure meaningful improvement and move the field closer to precision Dermatology for patients living with this debilitating condition. We are proud to see Mount Sinai Dermatology contributing to global research advancing care for hidradenitis suppurativa. 🌍🏥

The Mount Sinai Hospital

03/12/2026

Reconstructing full thickness defects of the nasal ala after Mohs micrographic surgery remains one of the most technically demanding challenges in cutaneous surgery. In a new report from the Icahn School of Medicine at Mount Sinai Dermatology surgical team, Dr. Jesse Lewin, Micrographic Surgery and Dermatologic Oncology fellow Dr. Alexandra Elder, and resident Dr. Marguerite Meariman present a thoughtful reconstructive approach using a superiorly based paranasal interpolation folded flap. In their case of a seventy four year old patient with a 1 x 0.8 cm full thickness alar rim defect following Mohs surgery for basal cell carcinoma, this technique restored structural support and nasal symmetry while avoiding a common reconstructive pitfall, transfer of hair bearing skin to the ala. 👃🔬✂️

📚 https://bit.ly/4s3quSd

Full thickness alar rim defects present a unique reconstructive challenge because the alar rim and lobule play a central role in maintaining nasal valve support. Even small distortions can result in visible notching and functional compromise. The authors demonstrate how a carefully designed paranasal interpolation flap can provide reliable vascular supply, appropriate tissue bulk, and an excellent color and texture match. The flap is elevated along the nasolabial fold, folded to recreate both the mucosal and external components of the ala, and later divided after vascular integration. At follow up, the patient demonstrated excellent healing with restoration of contour and preservation of nasal architecture. 🧠🧬

Techniques such as this highlight the precision required in modern Dermatologic surgery and the importance of thoughtful flap design when restoring both function and cosmesis after skin cancer surgery. Swipe to the second image to see our team’s fantastic cosmetic result and appreciate how careful reconstruction can preserve nasal symmetry while maintaining the critical structural support of the alar rim. 🏥✨

The Mount Sinai Hospital

03/10/2026

Shruti Naik, PhD, will present “Duplicate Forging a New Therapeutic Frontier at the Intersection of Immunology and Regenerative Medicine” at the Dean’s Select Seminar Series: Monday, April 6, 4-6 pm. Details: https://bit.ly/DrNaikDeansSeminar

Mount Sinai’s mission is to radically advance biomedical science and healthcare through scholarly inquiry, collaborative learning, and humanism. The Dean’s Select Seminar Series promotes this vision. Each event features a 50-minute presentation by a leading member of the Mount Sinai faculty or occasionally an invited guest, followed by a festive reception to provide opportunities to connect with the speaker, Mount Sinai leadership, and colleagues.

03/04/2026

Alopecia Areata Symposium: Towards Better Treatments in AA—
A Unique Educational Symposium on Alopecia Areata and Scarring Alopecia for Physicians and Patients with Live Patient Testimonials
Join us!
When: Thursday, April 23, 2026 | 4:30-8:00 pm
Where: Mount Sinai Goldwurm Auditorium
1425 Madison Avenue, 1st floor (Corner of 98th Street)
Register now: https://www.surveymonkey.com/r/VPMXRR5
FREE ATTENDANCE—REGISTRATION REQUIRED
Light Refreshments will be served.
We invite all alopecia areata patients, their friends and family, and health care providers to come and hear how the community copes with the challenges of this condition.
Dermatologists who are experts in Alopecia Areata will discuss new developments and treatments for:
• Alopecia Areata
• Scarring Alopecia
• Androgenetic Alopecia
Insightful presentations include:
• The Epidemiology of Alopecia Areata and Risk Factors Associated with Increased Risk to Develop Alopecia Areata
• Alopecia Areata as a Systemic Disease and Associated Comorbidities
• Clinical Trials for Alopecia Areata
• Pathophysiology of Alopecia Areata and the Role of Various Immune Pathways in the Disease

• Live Patients’ Testimonials with Adult and Pediatric Patients will be presented.
• Physicians’ Panel of experts will lead Discussion and Q & A.

For more information call: (212) 659-9530 or email: Dermatology@mountsinai.org

02/26/2026

When it comes to immunity, children aren’t “small adults".
A new clinic-to-lab study by Dr. Yue Xing and Dr. Shruti Naik with Dr. Emma Guttman and Dr. Madeline Kim, and a multi-institutional team including Weil Cornell Medicine, tackles a long-standing clinical puzzle: why eczema so often begins in childhood and frequently precedes asthma, food allergy and other allergic disease.

This work was only possible through a true clinic-to-lab collaboration—where insights from pediatric patients shaped the questions asked in the lab,

The team showed that infant skin dendritic cells are biologically wired to overreact to allergens, activating inflammatory T cells and initiating eczema. But these immune signals don’t stay confined to skin, helping to explain how an early dermatologic condition can evolve into systemic allergy over time.

A major advance for dermatology and a powerful example of how patient observations can uncover upstream immune mechanisms with the potential to prevent disease before it spreads from skin to other organs.
Details: https://bit.ly/3P4OsO0
Press release: https://bit.ly/47equWT
Icahn School of Medicine at Mount Sinai

02/25/2026

We are ranked No. 3 in NIH research funding in Dermatology for 2025 by the Blue Ridge Institute for Medical Research (BRIMR).
When Dr. Emma Guttman became chair of the Department in 2021, the BRIMR ranking was No. 23 in 2020. Within only 5 years we rose to No. 3. This new ranking shows the explosive growth ↗️ of our research output and reputation.
This is a testament to the prestige & rigor of our academic research ahead of many premier institutions. Special thank you to all our P*s and our grant support staff for their hard work and dedication. 👏
Icahn School of Medicine at Mount Sinaii

02/21/2026

Dr. Emma Guttman presented ”Atopic Dermatitis Treatment Update” and was on a Panel Q & A at Masterclasses in Dermatology Annual Meeting 2026 in Sarasota, FL.
Masterclasses in Dermatology is designed to help clinicians translate emerging scientific research into better patient care.
Masterclasses in Dermatology

02/20/2026

Dr. Brian S. Kim reviews how itch is no longer viewed as a purely “skin level” symptom, it is a neuroimmune circuit where sensory neurons and immune cells actively amplify one another, especially in type 2 inflammatory disease. 🧠🧬 The article connects key clinical patterns (histaminergic vs nonhistaminergic itch, hyperknesis and alloknesis) to modern targets that are reshaping care in atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. 🩺✨🐝

📚https://tinyurl.com/3ekbb5sf

A major theme is that mast cells are not just bystanders, they are wired into itch pathways through KIT dependent survival signals and mediators like histamine, tryptase, IL-13, and IL-31. 🧫🔥 The authors also highlight how type 2 cytokines (IL-4, IL-13, IL-31) can directly activate or sensitize pruriceptors, helping explain why antihistamines often fall short in chronic inflammatory itch. 🧪⚡ Therapeutically, this framework clarifies why targeting IL-4Rα or IL-13 can relieve itch so effectively, and why IL-31RA blockade can deliver rapid antipruritic benefit even when skin inflammation improves more slowly. 🎯💉

The review also points to the next wave of antipruritic innovation: JAK signaling in neurons (with JAK1 as a key node), BTK inhibition downstream of FcεRI in urticaria biology, and mast cell depletion strategies via anti-KIT approaches now advancing in trials. 🧠🔍 Finally, opioid receptor pathways (MOR and KOR balance) and agents like KOR agonists underscore that itch biology spans immunology, neuroscience, and systemic disease. 🧩

Why this matters: itch is often undermeasured but drives sleep loss, mental health burden, and disease flares through the itch scratch cycle. A circuit based understanding supports more precise, mechanism aligned treatment selection and speeds translation from bench discoveries to bedside relief. ✅📈

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

02/18/2026

Dr. Benjamin Ungar, Dr. Emma Guttman-Yassky, and an international expert group synthesized the state of the science in alopecia areata, a common autoimmune, non-scarring hair loss disorder with major psychosocial burden. 💇‍♀️🧑‍⚕️🧬 The authors highlight that lifetime risk is ~2%, disease can range from a single patch to alopecia totalis or universalis, and comorbidities are frequent, including atopic disease, autoimmune conditions, and depression or anxiety. 🧠🩺📊 The message is clear, alopecia areata is not “just hair,” it is systemic immune dysregulation with real quality-of-life impact.

📚https://tinyurl.com/aa75284

Mechanistically, the Primer walks through collapse of hair follicle immune privilege and the downstream inflammatory cascade, including cytotoxic T cell activity, IFNγ, IL-2, IL-15, and broader pathway contributions that also include TH2 signals in subsets, especially those with atopy. 🔥 On the clinical side, it reviews practical diagnosis (including trichoscopy features) and modern severity assessment tools, then maps a rapidly evolving treatment landscape. ✅💊 In particular, it contextualizes the therapeutic shift driven by JAK inhibition, with FDA approval milestones for severe alopecia areata in adults (2022) and adolescents (2023), plus additional approvals and late-stage trials expanding options. The authors also underscore ongoing gaps, including limited approved therapies for mild-to-moderate disease, relapse after treatment cessation, and the need for more inclusive trials to address disparities in presentation and care. 🌍🔍

Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital

02/16/2026

Dr. Saakshi Khattri and colleagues at Icahn School of Medicine at Mount Sinai report one of the largest single-center case series to date on systemic treatment for generalized granuloma annulare (GGA), a rare, often treatment-resistant form of GA. 🧴🩺 In the Journal of Drugs in Dermatology, they retrospectively reviewed 22 adults with recalcitrant GGA treated with biologics or oral JAK inhibitors, after many had already tried topical or intralesional steroids, hydroxychloroquine, antibiotics, topical ruxolitinib, and phototherapy. This cohort reflects the real-world challenge of GGA, persistent disease, limited guidance, and a growing need for rational systemic options.

📚 https://bit.ly/4kNpWwP

What did they find? Across therapies, most patients had at least some improvement in erythema, induration, or lesion burden, and 59.1% achieved a marked response or clinical remission. Adalimumab was the most commonly used (11 patients), with 63.6% reaching marked response or remission. Dupilumab (8 patients) produced moderate or better responses in 62.5%, including 1 remission. Oral JAK1 inhibitors stood out, all patients on upadacitinib (5 patients) improved, with 80% achieving marked response or remission, and abrocitinib led to remission in 1 of 2 patients. Two patients who did not respond well to adalimumab achieved remission after switching to an oral JAK inhibitor, and 1 patient who relapsed on adalimumab achieved remission after adding dupilumab. Reported adverse events were uncommon and no serious adverse events were described.

GGA has been a therapeutic orphan for decades, and these data support a pathway-informed approach. GA biology is linked to Th1, Th2, Th17, Th22 and JAK-STAT signaling, making targeted immunomodulation biologically plausible and clinically relevant. This series helps clinicians think more concretely about sequencing and escalation, while reinforcing the need for prospective trials and evidence-based guidelines in this difficult disease. 🧠📊

02/13/2026

A recent editorial in Melanoma Management by Dr. Andrew L. Ji and Dr. Nicholas Gulati from Icahn School of Medicine at Mount Sinai, spotlights brain organoid technology as a next step for modeling melanoma brain metastases. 🧠🧫🧬 Melanoma accounts for most skin cancer related deaths despite representing about 1% of skin cancers, and brain metastases develop in roughly 60% of metastatic cases. 🎗️🧠 Current standards like neurosurgery and radiation carry substantial morbidity with limited survival gains, and even with modern checkpoint inhibition plus BRAF or MEK targeted therapy, outcomes remain far from where they need to be. 💊📉 The authors argue that part of the gap is preclinical modeling, mouse systems and 2D cultures miss critical human brain microenvironment biology, and tumor organoids often lack a human neural context, vasculature, and a functional blood brain barrier. 🔬🧩🧱

📚 https://bit.ly/49yL05c

Why this matters for Dermatology and translational oncology, brain organoids derived from human iPSCs can be engineered to include vascular features, blood brain barrier components, and resident immune cells such as microglia, creating a more physiologic platform to study seeding, invasion, and treatment pe*******on in real time. 🚦🩸🧠 The piece also lays out a precision pathway, integrating patient derived melanoma cells into mature organoids to test immunotherapy, targeted therapy, radiation, and combinations before clinical decisions, and to dissect resistance mechanisms specific to the brain niche. 🎯🧪📸

Challenges remain, including maturation, cost, culture time, and batch variability, but the direction is clear, humanized brain models could sharpen the translation of promising therapies from bench to bedside for melanoma brain metastases. 🧭🏥✨

The Mount Sinai Hospital

02/12/2026

A multidisciplinary team from the Departments of Psychiatry and Dermatology at the Icahn School of Medicine at Mount Sinai found that the serum of patients with major depressive disorder (MDD) shares immune abnormalities with inflammatory skin diseases, most notably the common Th2 immune pathway that is implicated in atopic dermatitis. The study suggests that for patients with MDD and other psychiatric conditions, drugs already approved for skin conditions might offer a new treatment approach.

If we can successfully treat inflammation in the skin, could similar drugs help treat inflammation-related depression and other conditions in the brain? This study gives justification that more human studies and clinical trials are needed. Combining our collective expertise with a multidisciplinary approach, can help move this line of research forward.
Press release: https://bit.ly/4aMDCVp
Details: https://www.nature.com/articles/s41380-025-03383-5

Mount Sinai Dermatology

03/16/2026

03/12/2026

03/10/2026

03/04/2026

02/26/2026

02/25/2026

02/21/2026

02/20/2026

02/18/2026

02/16/2026

02/13/2026

02/12/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category